Details: pack, label wording, sources, registration
Kinoron 100000 IU/dose, Powder
at least 100, 000 IU/dose lyophilisate, N4 for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Adjunctive treatment of labelled canine distemper, viral enteritis and infectious hepatitis
3.8/10
Poor / unconvincing
Details →
vetman assessment
Kinoron
×
at least 100, 000 IU/dose lyophilisate, N4 for dogs
Assessed clinical scope Dog · Adjunctive treatment of labelled canine distemper, viral enteritis and infectious hepatitis · SC,IM
Care setting Veterinarian-directed adjunct in diagnosed infectious disease with isolation, intensive supportive care and cause-specific monitoring
vetman score
3.8/10
Poor / unconvincing
Evidence confidence: Low
Georgia: Yes, veterinary · № 000122 · Verified on 23 Oct 2026
A weak adjunct with plausible interferon biology but no controlled exact-product outcome and a heavy multi-injection course. It must never delay isolation, diagnostics, fluids, nutrition, antiemesis, seizure control or other indicated care.
Regulatory and scientific credibility 5.0/10
A current official manufacturer instruction and active Georgian registration verify exact identity, potency floor, species, routes and schedules. Public exact-product assessment data, batch-potency detail and internationally recognised exact authorisations remain absent.
Clinical efficacy 2.5/10
Interferon biology and canine parvovirus trials with high-dose IV recombinant feline interferon-omega support only indirect plausibility. No controlled Kinoron alfa-2b outcome was found; current parvovirus guidance finds interferon-omega unproven overall, distemper care is supportive, and infectious-hepatitis evidence is absent.
Safety and tolerability 4.0/10
The exact label reports good tolerance and allergy as the principal stop, but supplies no adverse-event frequencies, overdose information, target-animal laboratory safety margin, immunogenicity/neutralising-antibody data or transparent evidence behind broad reproductive and co-medication claims.
Clinical practicality 3.5/10
Treatment requires twice-daily SC/IM injections for three days, then every-other-day injections for 7-10 days, after 2 ml reconstitution per vial. At the label extremes this consumes about 10-22 vials at <=10 kg or 20-33 vials above 10 kg—three to nine N4 packs—plus cold-chain, asepsis, restraint and injection-site monitoring.
Full-course cost-effectiveness -
A current exact Georgian price and complete weight-adjusted course comparison were not verified; cost is excluded from the denominator. Pack consumption is still disclosed as a treatment-burden fact.
Important safety and use flags
Complete treatment boundary: the label names canine distemper, viral enteritis and infectious canine hepatitis at the first clinical signs. Confirm the disease and severity; this is an adjunct, not a stand-alone antiviral or a substitute for intensive supportive care. Reconstitute one one-dose vial with exactly 2 ml sterile distilled water, water for injection or sterile saline and mix to complete dissolution. Use aseptic technique and do not infer that the 10 ml vial capacity is the dose volume. Dose by the exact two-band table: <=10 kg receives 2-4 ml (1-2 vials/doses); >10 kg receives 4-6 ml (2-3 vials/doses). The label gives no rule for choosing within either range and no upper weight band; document the selected dose rather than inventing mg/kg interpolation. Give twice daily for the first 3 days, then once every other day for 7-10 days. Count every administration and vial in advance; an N4 carton is not a complete treatment course at any labelled dose. Store unopened product protected from light at 2-10 C. The current instruction says a prepared solution may be refrigerated for no more than 24 hours, but also says opened-vial unused remnants are not storable; prefer immediate use of whole reconstituted one-dose vials and do not pool or retain an unvalidated partial vial. Stop for hypersensitivity and treat clinically. The label states adverse effects are generally not observed, but gives no frequency denominator, overdose data or robust target-animal safety margin; monitor temperature, injection site, systemic reaction and disease trajectory. The label states no special restriction in pregnancy, lactation or young animals and permits combination with any chemotherapy or antibiotic. These unusually broad claims lack public interaction, reproduction, juvenile or immunogenicity datasets; make patient-specific decisions and do not assume every combination is tested. For parvoviral enteritis prioritise isolation, fluid/electrolyte and glucose correction, antiemesis, early nutrition and indicated antimicrobials/monitoring. For distemper prioritise nursing, hydration/nutrition, secondary-infection and seizure control; neurologic disease may progress despite treatment. Do not transfer Virbagen Omega evidence or dose: that authorised comparator is recombinant feline interferon-omega 2.5 MU/kg IV for three days in canine parvovirosis, versus Kinoron interferon alfa-2b >=0.1 MU per vial given SC/IM on a different schedule. Georgia registers the exact N4 product through 14 July 2027. It is not authorised in the audited EU/GB/US databases; FDA approved: no. The NFA 8 ml versus current instruction 10 ml vial-capacity discrepancy does not alter the one-dose content or 2 ml reconstitution but remains visible. Assessment sources +
Close
Dog
Pre-exposure prophylaxis against the labelled canine viral infections
3.2/10
Poor / unconvincing
Details →
vetman assessment
Kinoron
×
at least 100, 000 IU/dose lyophilisate, N4 for dogs
Assessed clinical scope Dog · Pre-exposure prophylaxis against the labelled canine viral infections · SC,IM
Care setting Veterinarian-directed outbreak/exposure management alongside vaccination, isolation, hygiene and surveillance
vetman score
3.2/10
Poor / unconvincing
Evidence confidence: Low
Georgia: Yes, veterinary · № 000122 · Verified on 23 Oct 2026
A legally traceable but unconvincing prophylactic option: no direct protection evidence or objective duration endpoint was found, while repeated injections must never displace vaccination and outbreak control.
Regulatory and scientific credibility 5.0/10
A current official manufacturer instruction and active Georgian registration verify exact identity, potency floor, species, routes and schedules. Public exact-product assessment data, batch-potency detail and internationally recognised exact authorisations remain absent.
Clinical efficacy 1.0/10
No controlled exact-product prophylaxis study or validated exposure endpoint was found. Mechanism and treatment studies of different interferons cannot establish protection, and current prevention rests on vaccination plus infection-control measures.
Safety and tolerability 4.0/10
The exact label reports good tolerance and allergy as the principal stop, but supplies no adverse-event frequencies, overdose information, target-animal laboratory safety margin, immunogenicity/neutralising-antibody data or transparent evidence behind broad reproductive and co-medication claims.
Clinical practicality 2.5/10
Each vial must be reconstituted aseptically in 2 ml and injected SC/IM every other day for an undefined threat period. The two broad weight bands permit 1-2 or 2-3 whole vials per administration without selection criteria, so dose precision, cold chain, repeated restraint and N4 pack turnover are substantial burdens.
Full-course cost-effectiveness -
A current exact Georgian price and complete weight-adjusted course comparison were not verified; cost is excluded from the denominator. Pack consumption is still disclosed as a treatment-burden fact.
Important safety and use flags
Complete prophylaxis boundary: the label names distemper, viral enteritis and infectious canine hepatitis during an infection threat. Use only inside a veterinarian-led exposure plan; it is not a vaccine, post-exposure guarantee or substitute for isolation, disinfection and surveillance. Reconstitute one one-dose vial with exactly 2 ml sterile distilled water, water for injection or sterile saline and mix to complete dissolution. Use aseptic technique and do not infer that the 10 ml vial capacity is the dose volume. Dose by the exact two-band table: <=10 kg receives 2-4 ml (1-2 vials/doses); >10 kg receives 4-6 ml (2-3 vials/doses). The label gives no rule for choosing within either range and no upper weight band; document the selected dose rather than inventing mg/kg interpolation. Give every other day only while a defined exposure threat persists. Establish the threat, objective review date and stop criterion before starting; indefinite prophylactic injections are not a valid interpretation of the label. Store unopened product protected from light at 2-10 C. The current instruction says a prepared solution may be refrigerated for no more than 24 hours, but also says opened-vial unused remnants are not storable; prefer immediate use of whole reconstituted one-dose vials and do not pool or retain an unvalidated partial vial. Stop for hypersensitivity and treat clinically. The label states adverse effects are generally not observed, but gives no frequency denominator, overdose data or robust target-animal safety margin; monitor temperature, injection site, systemic reaction and disease trajectory. The label states no special restriction in pregnancy, lactation or young animals and permits combination with any chemotherapy or antibiotic. These unusually broad claims lack public interaction, reproduction, juvenile or immunogenicity datasets; make patient-specific decisions and do not assume every combination is tested. Prioritise current core vaccination and outbreak control. Interferon injection after or around vaccination is not established here; do not use it to shorten vaccine schedules, override maternal-antibody windows or certify immunity. Do not transfer Virbagen Omega evidence or dose: that authorised comparator is recombinant feline interferon-omega 2.5 MU/kg IV for three days in canine parvovirosis, versus Kinoron interferon alfa-2b >=0.1 MU per vial given SC/IM on a different schedule. Georgia registers the exact N4 product through 14 July 2027. It is not authorised in the audited EU/GB/US databases; FDA approved: no. The NFA 8 ml versus current instruction 10 ml vial-capacity discrepancy does not alter the one-dose content or 2 ml reconstitution but remains visible. Assessment sources +
Close
Composition / strength
Interferon alfa 100000 IU/dose
Administration route
Subcutaneous, Intramuscular
Manufacturer (register)
Joint stock company Mosagrogen, Russia
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 688, 19 Oct 2026.
Registration
Georgia
Yes, veterinary
In force until 14 Jul 2027
Veterinary (National Food Agency)
In the register: კინორონი®
№ 000122
Verified on: 23 Oct 2026
EU
No
UK
No
US
No
Controlled in Georgia
Unknown
Dog
Weight Viral Infection Prophylaxis · Subcutaneous / Intramuscular Viral Infection Treatment · Subcutaneous / Intramuscular
up to 10 kg
2–4 ml 2–4 ml
over 10 kg
4–6 ml 4–6 ml
Viral Infection Prophylaxis · Subcutaneous / Intramuscular (every other day until the infection threat has passed): Reconstitute each one-dose vial in exactly 2 ml sterile distilled water, water for injection or saline. Give 2-4 ml (1-2 reconstituted doses) SC or IM. A prepared solution may be refrigerated for no more than 24 hours. The registered uses are canine distemper, viral enteritis and infectious hepatitis in dogs. Do not use with hypersensitivity; veterinary diagnosis and a treatment plan remain essential.Viral Infection Treatment · Subcutaneous / Intramuscular (twice daily for the first 3 days, then once daily every other day for 7-10 days): Reconstitute each vial in 2 ml and give 2-4 ml (1-2 reconstituted doses) SC or IM at the first clinical signs. The registered uses are canine distemper, viral enteritis and infectious hepatitis. This is adjunctive immunomodulatory treatment, not a substitute for diagnosis or indicated supportive/antimicrobial care.
Source:
Kinoron label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Kinoron lyophilisate - current official veterinary instruction
Mosagrogen official product information; instruction approved 4 September 2024, 2024
